Tecan Group AG · SIX:TECN

Tecan — FY2014 Earnings Presentation

30 slides from Tecan's earnings presentation, Mar 18, 2015

  1. Slide 1: Full Year Results 2014 Analyst & Media Conference

    Zurich, March 18th 2015 Full Year Results 2014 Analyst & Media Conference

  2. Slide 2: Speakers

    Speakers Dr. David Martyr, CEO Dr. Rudolf Eugster, CFO

  3. Slide 3: Agenda

    Tecan Full Year Results 2014 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p3

  4. Slide 4: Financial Performance 2014

    Tecan Full Year Results 2014 Financial Performance 2014 • Solid recovery in H2 2014 after difficult H1 in Partnering Business • Strong Order Entry in Partnering Business towards year-end • Despite good sales development in H2, organic full-year sales growth below original expectations • Sales from I

  5. Slide 5: Operating Highlights 2014

    Tecan Full Year Results 2014 Operating Highlights 2014 • Significant progress in major development programs • Launch of the Fluent™ laboratory automation family, Tecan’s next generation liquid handling platform • Launch of the ORTHO VISION™ Analyzer in the Partnering Business (OrthoClinical Diagnost

  6. Slide 6: Agenda

    Tecan Full Year Results 2014 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p6

  7. Slide 7: 2014 Order Entry and Sales Performance

    Tecan Full Year Results 2014 2014 Order Entry and Sales Performance Order Entry FY 2014 • Order Entry H2 2014 vs. H2 2013 417.4 420 • +12.2% in Swiss Francs 410 • +12.2% in local currencies 400 • Organic +7.5% in local currencies 390 386.1 380 • Order Entry FY 2014 vs. FY 2013 • +8.1% in Swiss Franc

  8. Slide 8: 2014 Segment Sales

    Tecan Full Year Results 2014 2014 Segment Sales Sales (in CHF millions) • Life Sciences Business: 250.0 236.3 • H2 2014: Sales up by 7.3% in CHF and 7.7% 225.0 223.7 higher in local currencies (LC) 200.0 • Organic sales growth of +0.4% in LC 2013 • FY 2014: Sales 5.6% above prior-year in CHF and 175

  9. Slide 9: 2014 Regional Sales Development

    Tecan Full Year Results 2014 2014 Regional Sales Development • Europe: YoY % +6.0% in LC Growth driven by double-digit increase in YoY % +4.6% in CHF YoY % the Life Sciences Business, helped by +19.2% in LC -3.0% in LC revenue contribution from IBL International. +14.2% in CHF Others -3.9% in CHF Sa

  10. Slide 10: FY 2014 Gross Profit

    Tecan Full Year Results 2014 FY 2014 Gross Profit Gross Profit (% = as a % of sales) • Gross profit increased to CHF 197.6m • CHF 8m or 4.2% above 2013 200 197.6 190 189.6 • Gross profit margin up by 70 bps 180 • Material cost savings, less non-standard 49.5% 48.8% cost of sales and costs of OEM CHF

  11. Slide 11: FY 2014 Cost Structure

    Tecan Full Year Results 2014 FY 2014 Cost Structure • Costs increased by CHF 5.8m (+4.2%) • Sales & Marketing up by 12.2% Operating Expenses (% = as a % of sales) • Investments in sales organization (mainly China and US), application specialists, marketing and product management to support product l

  12. Slide 12: FY 2014 EBIT and EBITDA

    Tecan Full Year Results 2014 FY 2014 EBIT and EBITDA EBIT and EBITDA (in CHF millions) 70 • EBIT increased to CHF 57.2m 67.5 65 65.1 • CHF 2.4m or 4.4% above 2013 60 • EBIT margin at 14.3% 57.2 EBIT 55 54.8 • Main effects impacting the EBIT margin: EBITDA (+) GP margin 65 bps better 50 (-) Expenses

  13. Slide 13: FY 2014 Segment Profitability

    Tecan Full Year Results 2014 FY 2014 Segment Profitability EBIT (in CHF millions) 45 • Life Sciences Business: 40.2 42.7 40 • EBIT increased substantially to CHF 40.2m 35 • EBIT margin increased to 16.3% 30 25 24.9 2013 • Positive volume effect and gross profit margin 20 18.4 2014 expansion 15 • Red

  14. Slide 14: FY 2014 Net Profit

    Tecan Full Year Results 2014 FY 2014 Net Profit Net Profit (% = as a % of sales) • Net profit of CHF 40.2m 50 • CHF 5.5m or 11.9% below 2013 45.7 • Decrease due to lower financial result 45 attributable to currency hedging 40.2 measures 40 CHF (mio) • Net profit margin reached 10.1% 10.1% 11.8% 35 •

  15. Slide 15: FY 2014 Financial Result Impact on Net Profit

    Tecan Full Year Results 2014 FY 2014 Financial Result Impact on Net Profit • Tecan’s hedging policy has been consistent for Percentage share of revenues and cost 2014* many years and is to cover the FX exposure of the operating activities % of revenues % of cost • Main net exposure is in USD USD 34%

  16. Slide 16: FY 2014 Basic Earnings per Share

    Tecan Full Year Results 2014 FY 2014 Basic Earnings per Share Basic Earnings per Share • Earnings per share decreased in line with Net Profit to CHF 3.63 4.50 4.16 4.00 3.63 3.50 • Average number of shares 3.00 2.50 outstanding: 11.1m (2013: 11.0m) CHF / share 2.00 1.50 1.00 0.50 0.00 2013 2014 p 16

  17. Slide 17: FY 2014 Cash Flow

    Tecan Full Year Results 2014 FY 2014 Cash Flow 48.2 -22.4 -15.5 -32.0 150.4 128.7 Cash at end of From Operations From Investments From Financing1 Investment Cash at end 2013 IBL International of 2014 • Cash flow from operations increased to CHF 48.2m (2013: CHF 27.9m) • Cash flow normalizing again,

  18. Slide 18: FY 2014 Key Figures

    Tecan Full Year Results 2014 FY 2014 Key Figures CHF m 2013 2014 Δ in % Sales 388.3 399.5 +2.9% Sales in local currencies 383.4 399.5 +4.2% Gross Profit 189.6 197.6 +4.2% in % of sales 48.8% 49.5% R&D 45.3 39.5 -13.0% in % of sales 11.7% 9.9% EBIT 54.8 57.2 +4.4% in % of sales 14.1% 14.3% EBIT (excl

  19. Slide 19: Agenda

    Tecan Full Year Results 2014 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p 19

  20. Slide 20: Review of Priorities 2014

    Tecan Full Year Results 2014 Review of Priorities 2014 Supporting Partnering Business • Considerably higher volumes of Dako Omnis customers with delivery ramp-up • ORTHO VISION™ Analyzer launched in October 2014 in Europe, Japan and Australia • Despite challenging environment, sales rose to Continue

  21. Slide 21: Priorities for 2015

    Tecan Full Year Results 2014 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new products Continue to expl

  22. Slide 22: Major Platform Launches in Two Product Lines

    Tecan Full Year Results 2014 Major Platform Launches in Two Product Lines Fluent™* Spark™* Next generation liquid handling All-new multimode microplate platform family reader platform Setting new standards for simplicity, Greater flexibility and increased productivity and confidence productivity for

  23. Slide 23: Priorities for 2015

    Tecan Full Year Results 2014 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new products Continue to expl

  24. Slide 24: Supporting Significant Delivery Ramp-Up

    Tecan Full Year Results 2014 Supporting Significant Delivery Ramp-Up Dako Omnis ORTHO VISION™* Advanced staining platform for Next-generation diagnostics tissue-based cancer diagnostics instrument used for blood typing Setting new standards with regard to flexibility, Transforming transfusion medici

  25. Slide 25: Priorities for 2015

    Tecan Full Year Results 2014 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new products Continue to expl

  26. Slide 26: Agenda

    Tecan Full Year Results 2014 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p 26

  27. Slide 27: Outlook for 2015

    Tecan Full Year Results 2014 Outlook for 2015 Sales Double-digit sales growth in local currencies Profitability EBITDA margin to increase by more than 100 bps Based on average FX rates of: 1.05 EUR/CHF and 0.92 USD/CHF pp27 27

  28. Slide 28: Tecan – Automating the Future of Labs

    Tecan Full Year Results 2014 Tecan – Automating the Future of Labs • Wave of new exciting products now reaching the market • Driving commercialization of next-generation platforms in both main product lines in the Life Sciences Business • Fluent™ Laboratory Automation Solution • Spark™ Multimode Mic

  29. Slide 29: Q&A

    Tecan Full Year Results 2014 Q&A IR iPad App News, financial reports, presentations, videos and more Next Events 2015: April 16: Annual Shareholder Meeting August 12: Half Year Results 2015 Contact Martin Braendle Vice President, Communications & IR Phone: +41 (0) 44 922 84 30 investor@tecan.com www

  30. Slide 30: Thank you for your attention

    Thank you for your attention Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solution

Tecan Group — FY2014 Earnings Presentation on 6ix